Corbus Pharmaceuticals Holding Stock Current Liabilities

CRBP Stock

USD 17.64 0.34 1.89%

Corbus Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Corbus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Corbus Stock. The fundamental analysis module provides a way to measure Corbus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Corbus Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

As of 11/27/2024, Total Current Liabilities is likely to drop to about 16.9 M. In addition to that, Non Current Liabilities Total is likely to drop to about 3.1 M.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Corbus Pharmaceuticals Holding Company Current Liabilities Analysis

Corbus Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis

Current Corbus Pharmaceuticals Current Liabilities

3.63 M

Most of Corbus Pharmaceuticals' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Corbus Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Corbus Current Liabilities Driver Correlations

Understanding the fundamental principles of building solid financial models for Corbus Pharmaceuticals is extremely important. It helps to project a fair market value of Corbus Stock properly, considering its historical fundamentals such as Current Liabilities. Since Corbus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Corbus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Corbus Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Net Receivables	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Property Plant Equipment	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt Total
Total Assets		0.84	0.67	-0.44	-0.69	0.52	0.69	0.82	1.0	0.23	0.76	0.87	0.78	0.76	0.79	0.17	0.85	0.1	0.03	0.35	-0.06
Total Stockholder Equity	0.84		0.3	-0.55	-0.27	0.2	0.25	0.44	0.86	-0.2	0.79	0.81	0.53	0.34	0.42	-0.25	0.49	0.5	0.47	0.56	0.36
Current Deferred Revenue	0.67	0.3		-0.31	-0.58	0.8	0.7	0.9	0.62	0.22	0.57	0.33	0.6	0.62	0.64	0.15	0.83	-0.26	-0.28	0.27	-0.08
Net Debt	-0.44	-0.55	-0.31		-0.14	-0.54	-0.06	-0.24	-0.45	0.37	-0.56	-0.34	-0.37	0.02	-0.22	0.39	-0.2	-0.07	-0.13	-0.4	-0.33
Retained Earnings	-0.69	-0.27	-0.58	-0.14		-0.39	-0.88	-0.82	-0.67	-0.8	-0.2	-0.65	-0.77	-0.99	-0.89	-0.75	-0.87	0.38	0.49	0.27	0.58
Accounts Payable	0.52	0.2	0.8	-0.54	-0.39		0.68	0.72	0.48	0.12	0.48	0.19	0.65	0.45	0.66	0.09	0.59	-0.55	-0.52	0.1	-0.09
Long Term Debt	0.69	0.25	0.7	-0.06	-0.88	0.68		0.88	0.65	0.61	0.33	0.51	0.83	0.89	0.93	0.57	0.87	-0.53	-0.59	-0.13	-0.45
Total Liab	0.82	0.44	0.9	-0.24	-0.82	0.72	0.88		0.78	0.42	0.56	0.59	0.81	0.85	0.85	0.35	0.98	-0.26	-0.32	0.14	-0.2
Total Current Assets	1.0	0.86	0.62	-0.45	-0.67	0.48	0.65	0.78		0.21	0.76	0.89	0.76	0.74	0.77	0.15	0.82	0.14	0.07	0.36	-0.05
Short Term Debt	0.23	-0.2	0.22	0.37	-0.8	0.12	0.61	0.42	0.21		-0.21	0.38	0.46	0.77	0.63	1.0	0.48	-0.59	-0.71	-0.55	-0.92
Common Stock	0.76	0.79	0.57	-0.56	-0.2	0.48	0.33	0.56	0.76	-0.21		0.59	0.44	0.28	0.38	-0.26	0.55	0.35	0.33	0.81	0.33
Net Tangible Assets	0.87	0.81	0.33	-0.34	-0.65	0.19	0.51	0.59	0.89	0.38	0.59		0.75	0.71	0.71	0.34	0.69	0.16	0.06	0.22	-0.18
Net Receivables	0.78	0.53	0.6	-0.37	-0.77	0.65	0.83	0.81	0.76	0.46	0.44	0.75		0.81	0.94	0.42	0.82	-0.4	-0.45	-0.07	-0.24
Capital Surpluse	0.76	0.34	0.62	0.02	-0.99	0.45	0.89	0.85	0.74	0.77	0.28	0.71	0.81		0.92	0.72	0.9	-0.37	-0.48	-0.21	-0.58
Deferred Long Term Liab	0.79	0.42	0.64	-0.22	-0.89	0.66	0.93	0.85	0.77	0.63	0.38	0.71	0.94	0.92		0.59	0.85	-0.49	-0.56	-0.16	-0.47
Short Long Term Debt	0.17	-0.25	0.15	0.39	-0.75	0.09	0.57	0.35	0.15	1.0	-0.26	0.34	0.42	0.72	0.59		0.41	-0.61	-0.72	-0.58	-0.93
Property Plant Equipment	0.85	0.49	0.83	-0.2	-0.87	0.59	0.87	0.98	0.82	0.48	0.55	0.69	0.82	0.9	0.85	0.41		-0.18	-0.26	0.13	-0.23
Net Invested Capital	0.1	0.5	-0.26	-0.07	0.38	-0.55	-0.53	-0.26	0.14	-0.59	0.35	0.16	-0.4	-0.37	-0.49	-0.61	-0.18		0.99	0.65	0.63
Net Working Capital	0.03	0.47	-0.28	-0.13	0.49	-0.52	-0.59	-0.32	0.07	-0.71	0.33	0.06	-0.45	-0.48	-0.56	-0.72	-0.26	0.99		0.67	0.72
Capital Stock	0.35	0.56	0.27	-0.4	0.27	0.1	-0.13	0.14	0.36	-0.55	0.81	0.22	-0.07	-0.21	-0.16	-0.58	0.13	0.65	0.67		0.59
Long Term Debt Total	-0.06	0.36	-0.08	-0.33	0.58	-0.09	-0.45	-0.2	-0.05	-0.92	0.33	-0.18	-0.24	-0.58	-0.47	-0.93	-0.23	0.63	0.72	0.59

Click cells to compare fundamentals

Corbus Current Liabilities Historical Pattern

Today, most investors in Corbus Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Corbus Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Corbus Pharmaceuticals current liabilities as a starting point in their analysis.

Corbus Pharmaceuticals Current Liabilities

Timeline

Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.

Competition

Predict Corbus Pharmaceuticals

Total Current Liabilities Over Time

Corbus Total Current Liabilities

Total Current Liabilities

16.85 Million

At this time, Corbus Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year.

In accordance with the recently published financial statements, Corbus Pharmaceuticals Holding has a Current Liabilities of 3.63 M. This is 99.79% lower than that of the Biotechnology sector and 99.33% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.95% higher than that of the company.

Corbus Current Liabilities Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Corbus Pharmaceuticals' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Corbus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Corbus Pharmaceuticals by comparing valuation metrics of similar companies.

Corbus Pharmaceuticals is currently under evaluation in current liabilities category among its peers.

Corbus Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Corbus Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Corbus Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Corbus Fundamentals

	Return On Equity	-0.51
	Return On Asset	-0.29
	Current Valuation	63.24 M
	Shares Outstanding	12.18 M
	Shares Owned By Insiders	0.70 %
	Shares Owned By Institutions	99.30 %
	Number Of Shares Shorted	2.4 M
	Price To Earning	(8.87) X
	Price To Book	1.46 X
	Price To Sales	163.32 X
	Gross Profit	(16.14 M)
	EBITDA	(44.44 M)
	Net Income	(44.6 M)
	Cash And Equivalents	66.23 M
	Cash Per Share	0.53 X
	Total Debt	20.88 M
	Debt To Equity	0.61 %
	Current Ratio	3.86 X
	Book Value Per Share	12.36 X
	Cash Flow From Operations	(36.1 M)
	Short Ratio	6.46 X
	Earnings Per Share	(4.71) X
	Target Price	59.5
	Number Of Employees	19
	Beta	2.57
	Market Capitalization	218.99 M
	Total Asset	28.27 M
	Retained Earnings	(436.68 M)
	Working Capital	(8.35 M)
	Current Asset	12.71 M
	Current Liabilities	3.63 M
	Net Asset	28.27 M

About Corbus Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Corbus Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corbus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corbus Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Corbus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Corbus Stock

0.95	FDMT	4D Molecular Therapeutics	Pair Corr
0.64	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.7	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

Moving against Corbus Stock

0.71	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.68	OPT	Opthea	Pair Corr
0.54	NAMS	NewAmsterdam Pharma	Pair Corr
0.38	PHVS	Pharvaris BV	Pair Corr
0.37	ESLAW	Estrella Immunopharma	Pair Corr

The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.

The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Corbus Stock Analysis

When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC